A 2-es típusú diabetesben szenvedök antidiabetics terápiája az akarbóz alkalmazásának helye

Translated title of the contribution: Antidiabetic therapy of patients with type 2 diabetes - The place of administration of acarbose

Research output: Contribution to journalArticle

Abstract

Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the preparation also reduces cardiovascular risk. If used as a monotherapy, acarbose does not cause hypoglycaemia. Flatulence and diaorrhea represent the main side effects. From a professional point of view, acarbose should be given if postprandial blood glucose excursions exceed 2.2 mmol/l.

Original languageHungarian
Pages (from-to)439-442
Number of pages4
JournalLege Artis Medicinae
Volume21
Issue number6-7
Publication statusPublished - Jun 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this